These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dosage, plasms concentration and antiarrhythmic effect of procainamide in sustained-release tablets. Arstila M; Katila M; Sundquist H; Anttila M; Pere E; Tikkanen R Acta Med Scand; 1974 Mar; 195(3):217-22. PubMed ID: 4595254 [No Abstract] [Full Text] [Related]
4. Pharmaceutical and pharmacokinetic principles in the formulation of a sustained-release procainamide tablet. Dahl SG; Fremstad D; Jacobsen S; Kvaleid I; Landmark KH; Lunde PK; Marthinsen AA; Nådland KJ; Waaler T Pharm Acta Helv; 1976; 51(7-8):204-8. PubMed ID: 967912 [No Abstract] [Full Text] [Related]
9. Procainamide absorption studies to test the feasibility of using a sustained-release preparation. Shaw TR; Kumana CR; Kaye CM; Padgham C; Kaspi T; Hamer J Br J Clin Pharmacol; 1975 Dec; 2(6):515-9. PubMed ID: 1234015 [TBL] [Abstract][Full Text] [Related]
10. Conventional and sustained-release procainamide: update on pharmacology and clinical use. Anderson JL Clin Ther; 1985; 7(5):618-40. PubMed ID: 3902240 [TBL] [Abstract][Full Text] [Related]
11. Conversion from intravenous procainamide to oral sustained release tablets in cardiac patients. Kalin ML; Babich MF; Klinke WP; Hui WK Can J Cardiol; 1990; 6(1):15-8. PubMed ID: 2310989 [TBL] [Abstract][Full Text] [Related]
12. Comparable steady-state bioavailability between two preparations of conventional-release procainamide hydrochloride. Kasmer RJ; Nara AR; Green JA; Chawla AK; Fleming GM Drug Intell Clin Pharm; 1987 Feb; 21(2):183-6. PubMed ID: 3829910 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of a sustained release procainamide preparation. Flanagan AD Angiology; 1982 Feb; 33(2):71-7. PubMed ID: 7039427 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic of procainamide in man. Koch-Weser J Ann N Y Acad Sci; 1971 Jul; 179():370-82. PubMed ID: 5285382 [No Abstract] [Full Text] [Related]
16. [Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation]. Pirovino M; Karlaganis G; Galeazzi RL Schweiz Med Wochenschr; 1980 Sep; 110(39):1415-9. PubMed ID: 6169144 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets. Graffner C; Johnsson G; Sjögren J Clin Pharmacol Ther; 1975 Apr; 17(4):414-23. PubMed ID: 1122683 [TBL] [Abstract][Full Text] [Related]
18. Predicting plasma procainamide concentrations resulting from a sustained-release preparation. DiPersio DM; Chow MS Clin Pharm; 1985; 4(2):186-91. PubMed ID: 3987218 [TBL] [Abstract][Full Text] [Related]
19. Prediction of steady-state trough serum procainamide concentrations after administration of a sustained-release procainamide preparation. Voelker MS; Nester TJ; Chow MS; O'Reilly D; Kluger J Ther Drug Monit; 1986; 8(2):184-8. PubMed ID: 3726932 [TBL] [Abstract][Full Text] [Related]
20. Sustained-release procainamide: use of serum concentrations to determine dosage. Reed WE; Cooper MW South Med J; 1985 Oct; 78(10):1190-3. PubMed ID: 4049036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]